Form 4: Zomedica Director Granted 1.82M SARs

Director Christopher R. MacLeod received 1,823,107 stock appreciation rights exercisable from Nov. 16, 2026 and expiring Nov. 16, 2035.

Summary

• On 2025-11-17, Director Christopher Ross MacLeod acquired 1,823,107 Stock Appreciation Rights (SARs) in Zomedica Corp. under transaction code A (grant).
• Each SAR has an exercise price of $0.10; no purchase price was paid for the grant.
• The SARs become exercisable on 2026-11-16 and expire on 2035-11-16.
• Following the transaction, MacLeod beneficially owns 1,823,107 derivative securities directly.
• No non-derivative securities transactions were reported.

Sentiment

Score: 5

Explanation: Routine insider equity grant with long-dated incentives; no operational or financial results disclosed.

Positives

• Equity award aligns director incentives with shareholder value creation.
• Long-dated term (expires 2035-11-16) supports retention and long-term focus.
• Clear exercisability date (2026-11-16) provides transparency on vesting/exercise timing.

Negatives

• Potential dilution to common shareholders upon SAR settlement, depending on plan terms, up to 1,823,107 underlying shares.
• Compensation tied to share price via derivatives may incentivize risk-taking.

Future Outlook

NA

Industry Context

Insider equity awards via SARs with approximately one-year to first exercisability and 10-year terms are common among small-cap life sciences and medtech companies. Such grants indicate incentive alignment but do not provide information on operating performance or near-term fundamentals.

Comparison to Industry Standards

• Compensation structure (SARs with ~1-year to first exercisability and a 10-year term) aligns with common U.S. small-cap practices; larger animal health peers (e.g., Zoetis, IDEXX) more often use RSUs/options but similar 10-year lives are standard.
• Grant size (1.823 million underlying shares) cannot be benchmarked without share count/market cap context; treated as neutral relative to industry norms absent that information.

Related Party Transactions

• Grant of 1,823,107 stock appreciation rights to Director Christopher Ross MacLeod on 2025-11-17 at a $0.10 exercise price, exercisable 2026-11-16 and expiring 2035-11-16.

Stakeholder Impact

• Aligns director incentives with shareholder returns through share price appreciation.
• Potential dilution upon SAR settlement up to 1,823,107 shares, subject to plan terms.

Next Steps

• SARs become exercisable on 2026-11-16.
• SARs expire on 2035-11-16.

Key Dates

Keywords

Zomedica, ZOMDF, Form 4, insider transaction, stock appreciation right, director grant, equity compensation, beneficial ownership, derivative securities